Analyzing MediciNova (NASDAQ:MNOV) & CorMedix (NASDAQ:CRMD)

CorMedix (NASDAQ:CRMD) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Profitability

This table compares CorMedix and MediciNova’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CorMedix	40.49%	40.52%	20.61%
MediciNova	-1,168.70%	-26.51%	-24.39%

Risk and Volatility

CorMedix has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.

Institutional and Insider Ownership

34.2% of CorMedix shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 3.5% of CorMedix shares are owned by insiders. Comparatively, 14.0% of MediciNova shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for CorMedix and MediciNova, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0	2	7	0	2.78
MediciNova	1	1	4	1	2.71

CorMedix presently has a consensus target price of $15.00, indicating a potential upside of 91.08%. MediciNova has a consensus target price of $7.75, indicating a potential upside of 457.55%. Given MediciNova’s higher possible upside, analysts plainly believe MediciNova is more favorable than CorMedix.

Valuation & Earnings

This table compares CorMedix and MediciNova”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71 million	1.96	$163.05 million	$2.14	3.67
MediciNova	$410,000.00	166.87	-$12.00 million	($0.21)	-6.62

CorMedix has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Summary

CorMedix beats MediciNova on 11 of the 15 factors compared between the two stocks.

About CorMedix

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

About MediciNova

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.